AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37575994 — intervention group
Group type: EXPERIMENTAL
Intervention: Omadacycline
Number of subjects: 239
Study 37575994 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin
Number of subjects: 239
Study 37576009 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC)
Number of subjects: 44
Study 37576009 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 44
Study 37576010 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated lesion segmentation algorithm using a fixed ADC threshold (≤620 × 10-6 mm)
Number of subjects: 108
Study 37576010 — intervention group
Group type: EXPERIMENTAL
Intervention: ADC threshold-based automated delineation
Number of subjects: 108
Study 37576010 — intervention group
Group type: EXPERIMENTAL
Intervention: ADC threshold-based automated delineation of very small lesions
Number of subjects: 108
Study 37576823 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate
Number of subjects: 0
Study 37576823 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 0
Study 37576973 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracellular vesicle-enriched preparations from participants with T1D
Number of subjects: 17
Study 37576973 — intervention group
Group type: COMPARATOR
Intervention: Extracellular vesicle-enriched preparations from healthy normal volunteers (Controls)
Number of subjects: 17
Study 37577112 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotrovimab 500 mg IM injection
Number of subjects: 1147
Study 37577112 — intervention group
Group type: COMPARATOR
Intervention: Sotrovimab 500 mg IV infusion
Number of subjects: 1147
Study 37577112 — intervention group
Group type: COMPARATOR
Intervention: Sotrovimab 250 mg IM injection
Number of subjects: 1147
Study 37577293 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance intraoperative hypotension (mIOH)
Number of subjects: 4776
Study 37577293 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-induction hypotension (pIOH)
Number of subjects: 4776
Study 37577293 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine usage, hypothermia, need for additional analgesics, nausea, and vomiting
Number of subjects: 4776
Study 37577293 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patients (≥65), patients with ASA≥2 status, those undergoing major surgery, experiencing unexpected bleeding, and exhibiting hypothermia at the end of anesthesia
Number of subjects: 4776
Study 37577514 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-level program for reducing cardiometabolic disease risk factors
Number of subjects: 0
Study 37577514 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured lifestyle change education program
Number of subjects: 0
Study 37577753 — intervention group
Group type: EXPERIMENTAL
Intervention: Delandistrogene moxeparvovec gene therapy
Number of subjects: 4
Study 37577753 — intervention group
Group type: COMPARATOR
Intervention: Control cohort (external)
Number of subjects: 4
Study 37577796 — intervention group
Group type: EXPERIMENTAL
Intervention: NCTF®135HA injections plus twice-daily anti-aging moisturizer cream
Number of subjects: 146
Study 37577796 — intervention group
Group type: COMPARATOR
Intervention: Anti-aging moisturizer cream alone
Number of subjects: 146
Study 37577798 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab (anti-IL-5 therapy)
Number of subjects: 0
Study 37577801 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (1 Hz rTMS)
Number of subjects: 60
Study 37577801 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 60
Study 37577801 — intervention group
Group type: EXPERIMENTAL
Intervention: Both active and sham groups
Number of subjects: 60
Study 37577817 — intervention group
Group type: EXPERIMENTAL
Intervention: PegIFNα-2b treatment for 68 weeks
Number of subjects: 40
Study 37577817 — intervention group
Group type: COMPARATOR
Intervention: PegIFNα-2b-based immunotherapy (two cycles with GM-CSF and vaccine treatment)
Number of subjects: 40
Study 37577933 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline KVSI (Kidney Venous Stasis Index)
Number of subjects: 216
Study 37577933 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IKVF pattern (Intrakidney Venous Flow pattern)
Number of subjects: 216
Study 37577933 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in KVSI from Doppler 1 to Doppler 2
Number of subjects: 216
Study 37577933 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in IKVF pattern severity from Doppler 1 to Doppler 2
Number of subjects: 216
Study 37577967 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow aspirate concentrate treatment
Number of subjects: 0
Study 37577967 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37578052 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless motility capsule test
Number of subjects: 48
Study 37578052 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires covering symptom severity and GI-specific quality of life
Number of subjects: 48
Study 37578052 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessments
Number of subjects: 48
Study 37578052 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon transit time measurement
Number of subjects: 48
Study 37578052 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of GI symptoms
Number of subjects: 48
Study 37578099 — intervention group
Group type: EXPERIMENTAL
Intervention: Burosumab treatment for 48 weeks
Number of subjects: 14
Study 37578099 — intervention group
Group type: EXPERIMENTAL
Intervention: Burosumab treatment for 144 weeks (exploratory analysis)
Number of subjects: 14
Study 37578099 — intervention group
Group type: EXPERIMENTAL
Intervention: Burosumab treatment for 144 weeks (SF-36 v2 scores)
Number of subjects: 14
Study 37578099 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative data from exit interviews with 8 participants
Number of subjects: 14
Study 37578100 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week web-based aerobic exercise programme
Number of subjects: 29
Study 37578113 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis for a duration of 24 hours
Number of subjects: 0
Study 37578113 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic prophylaxis for a duration longer than 24 hours
Number of subjects: 0
Study 37578188 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-lowering therapies
Number of subjects: 40339
Study 37578437 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooled Lumbar Radiofrequency Ablation (C-LRFA)
Number of subjects: 32
Study 37578437 — intervention group
Group type: COMPARATOR
Intervention: Facet Joint Injection (FIJ)
Number of subjects: 32
Study 37578485 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaso-occlusive crisis pain frequency
Number of subjects: 198
Study 37578485 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaso-occlusive crisis pain intensity
Number of subjects: 198
Study 37578485 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaso-occlusive crisis pain duration
Number of subjects: 198
Study 37578567 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative MRCP
Number of subjects: 180
Study 37578567 — intervention group
Group type: COMPARATOR
Intervention: Complementary perioperative imaging
Number of subjects: 180
Study 37578791 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo diterpene lactone meglumine (GDLM) administered once daily via intravenous infusion for 14 days.
Number of subjects: 3448
Study 37578791 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered once daily via intravenous infusion for 14 days.
Number of subjects: 3448
Study 37578791 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo diterpene lactone meglumine (GDLM) and placebo (both groups).
Number of subjects: 3448
Study 37578800 — intervention group
Group type: EXPERIMENTAL
Intervention: IPX203
Number of subjects: 630
Study 37578800 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release carbidopa-levodopa
Number of subjects: 630
Study 37578804 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid Closed-Loop System
Number of subjects: 0
Study 37578804 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37578827 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital self-efficacy training (EMI) combined with EMA
Number of subjects: 93
Study 37578827 — intervention group
Group type: COMPARATOR
Intervention: EMA only (Control group)
Number of subjects: 93
Study 37579053 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflutrozole 0.1 mg
Number of subjects: 271
Study 37579053 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflutrozole 0.3 mg
Number of subjects: 271
Study 37579053 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflutrozole 1.0 mg
Number of subjects: 271
Study 37579053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271
Study 37579053 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflutrozole (all doses)
Number of subjects: 271
Study 37579053 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflutrozole (0.1 mg, 0.3 mg, 1.0 mg)
Number of subjects: 271
Study 37579108 — intervention group
Group type: EXPERIMENTAL
Intervention: NicoBloc
Number of subjects: 45
Study 37579108 — intervention group
Group type: COMPARATOR
Intervention: Nicotine lozenge
Number of subjects: 45
Study 37579116 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 2 mg subcutaneously once-weekly for 6 weeks
Number of subjects: 3
Study 37579116 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard individual drug counseling
Number of subjects: 3
Study 37579130 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Serotonin Reuptake Inhibitors (SSRIs)
Number of subjects: 0
Study 37579130 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37579214 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF-1 (mecasermin, Increlex)
Number of subjects: 306
Study 37579253 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic testing for germline mutations in lung cancer patients
Number of subjects: 141
Study 37579304 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathic Communication Skills (ECS) training intervention
Number of subjects: 25
Study 37579572 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquefied petroleum gas (LPG) intervention for 26 months
Number of subjects: 200
Study 37579773 — intervention group
Group type: EXPERIMENTAL
Intervention: MenABCWY vaccine (0.5 mL, months 0 and 6)
Number of subjects: 1610
Study 37579773 — intervention group
Group type: COMPARATOR
Intervention: MenB-FHbp and MenACWY-CRM (two doses of MenB-FHbp and one dose of MenACWY-CRM)
Number of subjects: 1610
Study 37579773 — intervention group
Group type: EXPERIMENTAL
Intervention: MenABCWY vaccine
Number of subjects: 1610
Study 37579773 — intervention group
Group type: COMPARATOR
Intervention: MenB-FHbp
Number of subjects: 1610
Study 37579773 — intervention group
Group type: COMPARATOR
Intervention: MenB-FHbp and MenACWY-CRM
Number of subjects: 1610
Study 37579884 — intervention group
Group type: EXPERIMENTAL
Intervention: ABM
Number of subjects: 301
Study 37579884 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 301
Study 37579943 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary out-of-hospital CS admitted during off-hours
Number of subjects: 273
Study 37579943 — intervention group
Group type: COMPARATOR
Intervention: Secondary in-hospital CS
Number of subjects: 273
Study 37579943 — intervention group
Group type: COMPARATOR
Intervention: AMI related secondary in-hospital CS
Number of subjects: 273
Study 37580026 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine/Chloroquine
Number of subjects: 5
Study 37580026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 37580032 — intervention group
Group type: EXPERIMENTAL
Intervention: Homestead food production intervention (home gardening and poultry rearing, child nutrition and health counseling)
Number of subjects: 3276
Study 37580032 — intervention group
Group type: EXPERIMENTAL
Intervention: Homestead food production intervention
Number of subjects: 3276
Study 37580090 — intervention group
Group type: EXPERIMENTAL
Intervention: Online evidence-based leadership training
Number of subjects: 300
Study 37580090 — intervention group
Group type: COMPARATOR
Intervention: Conventional online training (reading material only)
Number of subjects: 300
Study 37580112 — intervention group
Group type: EXPERIMENTAL
Intervention: PIK3CA-related overgrowth spectrum (PROS) patients
Number of subjects: 267
Study 37580112 — intervention group
Group type: COMPARATOR
Intervention: Wilms tumor/nephrogenic rests
Number of subjects: 267
Study 37580112 — intervention group
Group type: COMPARATOR
Intervention: Other cancers
Number of subjects: 267
Study 37580231 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 50
Study 37580231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 37580232 — intervention group
Group type: EXPERIMENTAL
Intervention: Potato consumption <1/week
Number of subjects: 2208
Study 37580232 — intervention group
Group type: EXPERIMENTAL
Intervention: Potato consumption 1/week
Number of subjects: 2208
Study 37580232 — intervention group
Group type: EXPERIMENTAL
Intervention: Potato consumption 2-4/week
Number of subjects: 2208
Study 37580232 — intervention group
Group type: EXPERIMENTAL
Intervention: Potato consumption 5+/week
Number of subjects: 2208
Study 37580338 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban uninterrupted during cleaning procedures (53/68, 77.9%)
Number of subjects: 196
Study 37580338 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban interrupted for single tooth extractions (67/100, 67.0%)
Number of subjects: 196
Study 37580338 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban interrupted for multiple tooth extractions (16/30, 53.3%)
Number of subjects: 196
Study 37580338 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncleaning procedures with uninterrupted edoxaban (not specified)
Number of subjects: 196
Study 37580338 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall management of edoxaban during dental procedures
Number of subjects: 196
Study 37580338 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall bleeding rates during procedures
Number of subjects: 196
Study 37580352 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus apatinib (cohort 1)
Number of subjects: 72
Study 37580352 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus apatinib (cohort 2)
Number of subjects: 72
Study 37580352 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus apatinib
Number of subjects: 72
Study 37580498 — intervention group
Group type: EXPERIMENTAL
Intervention: MP-AzeFlu nasal spray (one spray per nostril twice daily for 14 days)
Number of subjects: 900
Study 37580498 — intervention group
Group type: COMPARATOR
Intervention: Azelastine hydrochloride nasal spray (AZE)
Number of subjects: 900
Study 37580498 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate nasal spray (FLU)
Number of subjects: 900
Study 37580498 — intervention group
Group type: EXPERIMENTAL
Intervention: MP-AzeFlu nasal spray
Number of subjects: 900
Study 37580534 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation to the cerebellar dentate nucleus combined with renewed physical rehabilitation
Number of subjects: 12
Study 37580610 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC)
Number of subjects: 53
Study 37580653 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial education paired with housing support and trauma-informed counseling
Number of subjects: 0
Study 37580653 — intervention group
Group type: EXPERIMENTAL
Intervention: Policy changes to address structural racism
Number of subjects: 0
Study 37580657 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV genotyping
Number of subjects: 834
Study 37580657 — intervention group
Group type: EXPERIMENTAL
Intervention: HDV genotyping
Number of subjects: 834
Study 37580658 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Emotions Training (PoET)
Number of subjects: 101
Study 37580658 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 101
Study 37580661 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib 8 mg once daily and Fluzoparib 150 mg twice daily until disease progression or intolerable toxicity
Number of subjects: 50
Study 37580663 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose of enteral cholecalciferol (10,000 IU/kg, maximum of 400,000 IU)
Number of subjects: 67
Study 37580663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 37580666 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted animation video for men aged 16-24 years
Number of subjects: 186113
Study 37580666 — intervention group
Group type: EXPERIMENTAL
Intervention: General animation video
Number of subjects: 186113
Study 37580666 — intervention group
Group type: COMPARATOR
Intervention: No video (control group)
Number of subjects: 186113
Study 37580739 — intervention group
Group type: EXPERIMENTAL
Intervention: Distorted Thoughts Scale (DTS)
Number of subjects: 119
Study 37580739 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive distortions as a mediator
Number of subjects: 119
Study 37580773 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib plus endocrine therapy (ET) including letrozole, fulvestrant, or tamoxifen with goserelin.
Number of subjects: 87
Study 37580777 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitors
Number of subjects: 76
Study 37580782 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic placement of ProGrip™ mesh in an onlay position
Number of subjects: 0
Study 37580782 — intervention group
Group type: COMPARATOR
Intervention: Standardized abdominal closure without mesh
Number of subjects: 0
Study 37580788 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week gamified family-based health and exercise intervention
Number of subjects: 80
Study 37580788 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 80
Study 37580795 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategies for PrEP delivery in MCH clinics
Number of subjects: 146
Study 37580795 — intervention group
Group type: EXPERIMENTAL
Intervention: Stakeholder engagement and prioritization of strategies
Number of subjects: 146
Study 37580795 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to PrEP delivery
Number of subjects: 146
Study 37580800 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal exercise program (IMT + NMES + pulmonary rehabilitation)
Number of subjects: 40
Study 37580800 — intervention group
Group type: COMPARATOR
Intervention: Inspiratory muscle training (IMT + pulmonary rehabilitation)
Number of subjects: 40
Study 37580800 — intervention group
Group type: COMPARATOR
Intervention: Neuromuscular electrical stimulation (NMES + pulmonary rehabilitation)
Number of subjects: 40
Study 37580800 — intervention group
Group type: COMPARATOR
Intervention: Standard pulmonary rehabilitation
Number of subjects: 40
Study 37580810 — intervention group
Group type: EXPERIMENTAL
Intervention: FBT-HT
Number of subjects: 90
Study 37580810 — intervention group
Group type: COMPARATOR
Intervention: FBT
Number of subjects: 90
Study 37580810 — intervention group
Group type: COMPARATOR
Intervention: FBT-MBSR
Number of subjects: 90
Study 37580815 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit and feedback (A&F) with individual-level clinician data, data relevant to MBC barriers, and information requested by data recipients.
Number of subjects: 6
Study 37580815 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit and feedback (A&F) with aggregate data summaries.
Number of subjects: 6
Study 37580815 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit and feedback (A&F) with data accuracy concerns addressed.
Number of subjects: 6
Study 37580831 — intervention group
Group type: EXPERIMENTAL
Intervention: High adherence to the Mediterranean diet (mediSCORE ≥ 6)
Number of subjects: 612
Study 37580831 — intervention group
Group type: COMPARATOR
Intervention: Low adherence to the Mediterranean diet
Number of subjects: 612
Study 37580831 — intervention group
Group type: EXPERIMENTAL
Intervention: High GRS with adherence to the Mediterranean diet
Number of subjects: 612
Study 37580831 — intervention group
Group type: EXPERIMENTAL
Intervention: Low GRS with adherence to the Mediterranean diet
Number of subjects: 612
Study 37580831 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction of GRS and adherence to the Mediterranean diet
Number of subjects: 612
Study 37580836 — intervention group
Group type: EXPERIMENTAL
Intervention: HCW-delivered Adolescent Transition Package (ATP) via phone delivery
Number of subjects: 0
Study 37580836 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptations made to the ATP
Number of subjects: 0
Study 37580836 — intervention group
Group type: EXPERIMENTAL
Intervention: Context adaptations
Number of subjects: 0
Study 37580836 — intervention group
Group type: EXPERIMENTAL
Intervention: Content adaptations
Number of subjects: 0
Study 37580836 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation process adaptations
Number of subjects: 0
Study 37580838 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 45
Study 37580838 — intervention group
Group type: COMPARATOR
Intervention: N-DEX (no dexmedetomidine)
Number of subjects: 45
Study 37580840 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed pipeline with novel feature selection strategies
Number of subjects: 101
Study 37580840 — intervention group
Group type: COMPARATOR
Intervention: Conventional pipeline reflecting common radiomics practice
Number of subjects: 101
Study 37580874 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric (ISO) task
Number of subjects: 38
Study 37580874 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric (CON) task
Number of subjects: 38
Study 37580874 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling (BIKE) task
Number of subjects: 38
Study 37580874 — intervention group
Group type: EXPERIMENTAL
Intervention: Last common stages performed in ISO
Number of subjects: 38
Study 37580874 — intervention group
Group type: EXPERIMENTAL
Intervention: Last common stages performed in BIKE
Number of subjects: 38
Study 37580874 — intervention group
Group type: EXPERIMENTAL
Intervention: Task failure
Number of subjects: 38